Sodium-glucose cotransporter-2 (SGLT2) inhibitors represent a relatively novel category of antihyperglycaemic agents (AHAs) utilized for managing T2DM by impeding glucose reuptake in the renal proximal tubules [10, 11]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.